SUPN News and Press, Supernus Pharmaceuticals Inc. From 11/08/22

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2022 Earnings Conference Call November 8, 2022 4:30 P.M. ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Cal...

Supernus Pharmaceuticals press release ( NASDAQ: SUPN ): Q3 GAAP EPS of $0.03 misses by $0.33 . Revenue of $177.35M (+19.4% Y/Y) beats by $4.87M . Third quarter 2022 Qelbree net product sales of $18.3 million increased 65% compared to second quarter of 202...

Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021 Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million to $40 million previously Increasing full year 2022 total revenues guidance to...

ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fina...

Supernus Pharmaceuticals ( NASDAQ: SUPN ) is trading 12.6% down premarket after the U.S. Food and drug Administration declined to approve its apomorphine infusion device, SPN-830, to treat motor fluctuations in Parkinson’s disease. The FDA has asked the comp...

ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration...

ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of...

Improving VBR performance numbers are discussed. 4 new buy signals are explained. Barnwell Industries is highlighted and analyzed in more detail. I have some good news to report. My VBR lists have outlined solid progress on the performance front. All 34 picks since incep...

Shares have fallen by 30% over 5 years and have risen by 15% in 2022. CNS specialist has a rich 30+ year history, varied approved product portfolio and deep pipeline. Qelbree launch in ADHD is looking successful out of the gate despite pandemic headwinds, with clear value proposit...

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2022 Earnings Conference Call August 4, 2022 16:30 ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Particip...